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of prostate cancer
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SUMMARY
: 
Low-dose rate brachytherapy (LDR - BT) is one of the radiation methods that is known for several years 
in treatment of localized prostate cancer. The main idea of this method is to implant small radioac-
tive seeds as a source of radiation, directly into the prostate gland. LDR brachytherapy is applied as 
a monotherapy and also used along with external beam radiation therapy (EBRT) as a boost. In most 
cases it is used as a sole radical treatment modality, however not as a palliative treatment. The applica-
tion of permanent seeds implants is a curative treatment alternative in patients with organ-confi ned 
cancer, without extracapsular extension of the tumour. Nowadays three kinds of radionuclide (I-125, 
Pd-103, Cs-131) are in use worldwide. This technique is particular favorite in United States, in Europe 
however, high-dose rate brachytherapy method (HDR BT) is more popular in early staged prostate 
cancer treatment ( as a boost). HDR-BT monotherapy for early stage prostate cancer is still an inves-
tigational treatment. As monotherapy LDR-BT seems to be a reliable choice for early stage prostate 
cancer, according to low morbidity rate good results and short hospitalization. It is curative alternative 
of radical prostatectomy or external beam radiation (i.e. 3D CRT, IMRT) with comparable long-term 
survival and biochemical control and most favorable toxicity. The aim of this publication is to describe 
methods, indications, complications and selected results of prostate cancer LDR brachytherapy. 
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INTRODUCTION
Patients with organ–confi ned prostate cancer 
are the appropriate candidates for curative 
treatment. There are several modalities that 
can be performed in order to treat this kind of 
cancer, such as: external beam radiation ther-
apy (EBRT), prostatectomy, cryotherapy or 
interstitial brachytherapy (BT). Brachythera-
py is one of the oldest methods and means im-
plantation of radioactive sources directly into 
the prostate. Permanent low dose rate (LDR) 
brachytherapy represents the most conformal 
radiation therapy and the number of patients 
referred for this radical treatment, grows rap-
idly, especially in the United States. In 1995 
brachytherapy has taken a part in prostate 
cancer treatment only in 5% (surgery – 65% 
procedures). Development of new techniques 
with new computer planning systems caused 
raising popularity of brachytherapy in US 
(36% in 2002 and >40% in 2004). Clinical and 
biochemical control rates of this method is 
comparable to radical prostatectomy or EBRT 
[1], however it is still not easly affordable ev-
erywhere because of high procedure costs. 
There are also several other adventages in 
LDR-BT. Better toxicity profi le with higher 
dose applying to prostate gland are the main 
points for brachytherapy in comparison with 
EBRT. Comparing with radical prostatectomy 
permanent seed’s implantation is a short, one 
day therapy with lower complication rate dur-
ing and after the procedure (bleeding, urinary 
incontinence, impotence). Specifi c selection of 
radioactive isotopes and their correct localiza-
tion, allows to deposit high dose into the pros-
tate tumour with rapid fall off the dose outside 
the area of treatment and – at the same time 
– allows to preserve organs at risk (OARs).
The beginning of interstitial brachytherapy 
as an idea of prostate cancer treatment has 
been found in the fi rst three decades of XX 
century. Pasteau and Denning published their 
data about treatment of patients, with the use 
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of single application of radium isotope through 
urethral catheter, directly into prostate gland 
[2, 3]. Unfortunately, high degree of compli-
cations excluded this technique from using it 
widely and stimulated other centers to look for 
more effi cient modalities.
Another period in history of this procedure 
can be localized in the 1970s. Permanent im-
plants were placed into malignant tumour af-
ter lymphadenectomy under surgeon s vision 
control. Several centers from US (Whitmore, 
Carlton) used iodine (I-125) and gold (Au-198) 
followed by external beam radiation therapy. 
After long follow- up study they found this 
method useless, because of unsatisfactory 
control of seeds position, radioactive danger 
for department staff and insuffi cient results in 
patients with locally advanced disease in com-
parison with EBRT alone [4].
The development of transrectal ultrasound 
(TRUS) in the late 80s, caused the emergence 
of new permanent seeds implantation tech-
nique. This procedure was elaborated by Holm 
and his coworkers using template guidance 
to help percutaneous needle implantation [5]. 
Concurrent technology progress including new 
radioisotopes, afterloading technique and con-
formal treatment planning, led to a signifi cant 
turning-point in brachytherapy and yet re-
newed physician s interest in the procedure of 
localized prostate cancer treatment. This tech-
nique was supported by improved dosimetry 
and offered the potential advantage by deliver-
ing a higher radiation dose directly to the pros-
tate, instead of external beam radiation. Rapid 
fall in the dose with a square of distance from 
the center of the isotope allows the use of doses 
into the tumour with concurrent protection of 
adjoin healthy tissues. These main facts permit 
to increase the concentration of the dose with 
application of higher, biological equivalent and 
fraction doses inside the prostate.
LDR-BT, a well-known technique all over 
the world is usually applied as a monotherapy. 
The reason why in Poland none of brachyther-
apy departments uses permanent implants is 
simple. High cost of an implantation do not 
transpose into higher 5-year disease–free sur-
vival rate of external beam radiation therapy 
or radical prostatectomy [6,7]. As it was men-
tioned above, it is still very exclusive form of 
treatment, where single procedure equals to 
seven weeks of EBRT with lower rates of late 
complication rates [8]. Satisfactory results of 
using LDR implants are possible due to punc-
tilious selection criteria of the patients.
The aim of this publication is to describe 
methods, indications, complications and se-
lected results of LDR-BT with the administra-
tion of permanent implants in prostate cancer 
treatment.
Indications and contraindications
The American Brachytherapy Society (ABS) 
has formed recommendations on consensus 
panel through clinical experience of experts 
and their analysis of published data. According 
to their publications the appropriate candidates 
for LDR monotherapy are patients with a high 
probability of organ-confi ned disease (Table 1). 
In this group with expected good results pre-
scribed doses for low dose rate brachytherapy 
Table 1. American Brachytherapy Society recommendations for transperineal permanent brachytherapy of prostate cancer [9]
Selection criteria BT recommended, good BT optional, fair BT investigational, poor 
PSA (ng/ml) < 10 10–20 >20
Gleason score 5-6 7 8-10
Stage T1c–T2a T2b–T2c T3
IPSS 0–8 9–19 >20
Prostate volume (cm3) < 40 40–60 >60
Q max (ml/s) >15 15–10 <10
Residual volume (cm3) >200
TURP + +
IPSS – International Prostate Symptom Score, Q – maximum urinary fl ow rate in ml/s, TURP – transurethral resection of the prostate 
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are 145 Gy for Iodine I-125 and 115-120 Gy for 
Palladium Pd-103 [9]. 
It is a general agreement not to apply LDR-
BT alone on patients with signifi cant risk of 
extraprostatic extension. Most of physicians 
defi nes this group by the presence of at least 
two main risk factors such as PSA level great-
er than 20 ng/ml, stage higher than T2b and/
or Gleason score greater than 7. According to 
ABS recommendations, these patients are to 
be treated with external beam radiation thera-
py in 40-50 Gy dose with brachytherapy boost 
of 110 Gy and 100 Gy depending on which 
EBRT dose was administered [9].
In general intermediate risk group (at least 
one of the risk factors mentioned above) isn’t 
an absolute contraindication of a single BT 
modality treatment. Good results published 
by several authors change the physicians pref-
erences to monotherapy combined with an-
drogen deprivation [10] However, to confi rm 
these observations studies are inevitable.
ABS also recommends LDR treatment 
in patients with at least 5 years of expected 
survival rate, what seems to be rather rela-
tive contraindication. According to their 
publication, neoadjuvant androgen depriva-
tion can decrease volume of the gland before 
brachytherapy [9]. No nodal involvement and 
absence of distant metastases are basic points 
in defi nition of organ-confi ned prostate cancer. 
Patients with disseminated disease can not be 
cured by radical treatment with this kind of 
radiation modality.
Transurethral resection of the prostate 
(TURP) is another relative contraindication 
for brachytherapy and is associated with high-
er rate (50%) of urinary incontinence after 
procedure. Nevertheless, several publications 
did not confi rmed these data and proved that 
risk of this kind of complication is less than 
10% [11]. Pubic arch interference as a result of 
large prostate may preclude adequate place-
ment of seeds, which is the reason why volume 
of prostate higher than 60 ml seems to be rela-
tive contraindication. Potential solution of this 
diffi culty in most cases is hormonal ablation 
for 3 months before the procedure. It causes 
less number of seeds during brachytherapy 
and may achieve their satisfactory distribu-
tion. Neoadiuvant hormone deprivation can 
also reduce signifi cant preoperative obstruc-
tive symptom, which is again a possible seri-
ous contraindication for brachytherapy and 
decrease the probability of postoperative 
acute urinary retention. Several authors re-
ported that downsizing the prostate gland by 
25-40% enables LDR procedure and reduces 
risk of obstructive complication in patients 
with large glands [12]. Problem with seeds 
implantation is likely to occure in obese pa-
tients when the equipment is not able to carry 
the weighty patients or is it not long enough to 
reach the base of prostate. Serious cardiac and 
respiratory tract diseases are not contraindi-
cations for brachytherapy and nowadays hav-
ing not much of a signifi cance. It may, however 
be noted that every older patient with these 
kind of problems requires more attention of 
physicians. Indications and contraindications 
according to ABS and ESTRO recommenda-
tions are summarized in table 2 a and b. 
Choosing isotope
There are several isotopes that are in use in 
medical world and each of them have unique 
energy and half life time. These physical 
characteristics determine the application of 
isotopes in two modalities in brachytherapy 
of prostate cancer - temporary (HDR) or per-
manent implants (LDR). Higher energy of 
an isotope equals better penetration into tar-
get tissue and according to that fact, the lo-
cation of single source in homogeneous dose 
achievement is not that important. On the 
other hand, the greater penetration of source 
radiation – the less protection of healthy tis-
sue and higher degree of complication rate as 
well as the necessity of reducing total dose to 
target volume. Ir-192 and Au-198 are the best 
examples of high energy radiation sources, 
which are potentially useful in brachytherapy 
as temporary implants. Low dose rate (LDR) 
energy sources such as I-125 or Pd-103, due to 
limited penetration, deposit prescribed dose 
into prostate gland with precision and sparing 
surrounding healthy tissues at the same time 
[13]. Because of this precised radiation, the 
LDR implants must be located with signifi cant 
caution to avoid areas of under dosage. Low 
dose rate energy allows the target to receive 
very high dose (120-160 Gy) of radiation at a 
longer time. This should be compared biologi-
cally to HDR monotherapy dose in shorter time 
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but with higher dose rate. Biologically higher 
dose can be given by HDR monotherapy but 
only with fractionation. The need of external 
beam therapy depends on the risk of extraca-
psular extension. With HDR monotherapy one 
could also give suffi cient dose to the prostate 
and can omit external beam therapy. Figure 1 
presents example of one permanent implant, 
fi gure 2 presents construction details of the 
I-125 implant. 
I-125 has a low energy (27 keV) with ini-
tial peripheral dose rate of 8 to 10 cGy/hr and 
a half-life of 60 days. According to this dose 
rate there have been several questions about 
effectiveness of permanent implants (spe-
cially I-125) in treatment of rapidly dividing 
tumours. Less differentiated malignancies 
with short half-lives may proliferate faster 
than  reducing tumor cells by I-125 treatment, 
which was proved by Freeman and his co-
workers in experiments [14]. There have been 
also several mathematical models constructed 
which compared degree of cell kill in relation 
with tumor doubling times for each radiation 
source. Moreover, Whitmore and al. published 
data that reveals the effectiveness and com-
parison of LDR and HDR implants of cell kill-
ing in rapid dividing tumors [15]. According 
to their studies, low-dose-rate permanent im-
plants are not so effective in this process as 
the HDR sources.
From 1986 new isotope – palladium 103 is 
in use in medical treatment. This radioactive 
source has almost the same physical charac-
teristics (energy – 21 keV) as the I-125. The 
main difference between Pd-103 and I-125 is 
shorter half-life of palladium (17 days) and that 
causes it’s initial dose rate higher of about 20 
cGy/hr. Few clinical data about this new iso-
tope presents the theoretical advantage of us-
Table 2 a
Selection criteria ABS ESTRO
PSA (ng/ml) <10 <10
Gleason score 2–6 5–
Stage T1–T2a T1c–T2a
AUA/IPSS Low (1–7) 0–8
Prostate volume (cm3) < 60 <50
Q max (ml/s) – >15
Residual volume (cm3) – <200
TURP + – –
Table 2 b
Selection criteria ABS ESTRO
Life expectancy <5 years <5 years
TURP Large and poorly healed defect Exclusion criteria
Distant metastases + +
Gland size (cm3) >60 >50
BPH – (Relative contraindication –
Pubic arch interference + (Relative contraindication + (Relative contraindication
Bleeding disorder – +
Positive seminal vesicles – (Relative contraindication –
IPSS – International Prostate Symptom Score, Q – maximum urinary fl ow rate in ml/s, TURP – transurethral resection of the prostate, 
BPH – benign prostate hypertrophy
Table 2. Indications (a) and contraindications (b) for permanent implant monotherapy according to ABS and ESTRO recom-
mendations [9]
Book 1.indb   153 2008-10-14   11:50:57
154 REP PRACT ONCOL RADIOTHER • 2008 • 13/3/: 150–167
REVIEW PAPER
ing palladium 103, along with radioprotection 
of medical workers (LDR) and high possibil-
ity of successful treatment in rapidly dividing 
tumors ( all comparing with I-125 ) [13]. That 
is a reason why Pd-103 should be the choice 
in presence of poorly differentiated prostate 
gland malignancies. Changing of treatment 
Isotope Half life Energy 90% of dose delivered Dose Range (Median dose)
Iodine-125 60 days 30.4 KeV 204 days 1. monotherapy 140-160 Gy     (145 Gy)
2. BT + 40-50 Gy EBRT            (100–120 Gy)
Palladium-103 17 days 22 KeV 58 days 1. monotherapy   110-120 Gy    (125 Gy)
2. BT + 50 Gy EBRT                  (60–90 Gy)
Cesium- 131 9.7 days 29 KeV 33 days 1. monotherapy                        (115 Gy)
- I-125  8 cGy/h (initial dose rate)         144 Gy in 10 months (total dose per time) 
- Pd-103  24 cGy/h (initial dose rate)    125 Gy in 3 months (total dose per time)
Table 3. Physical characteristics of used permanent implants
into high-dose-rate temporary brachythera-
py is well advisable. All this theoretical data 
needs to be verify by clinical multivariate 
trials. However, there are little data on the 
proliferation rate of human prostate cancer to 
confi rm this, nor any randomized trial data to 
show that one isotope is any better than the 
other.
Another isotope, Cesium-131 (Cs-131) was 
introduced at leading cancer treatment hos-
pitals in United States in October 2004 [16]. 
This isotope has been used in almost 50 loca-
tions across the US because of its useful char-
acteristics in prostate cancer treatment. Cesi-
um-131 transmits radiation dose to the target 
faster than other isotope seeds mentioned 
above. Thanks to that it became possible for 
patients to receive higher initial therapeutic 
dose with faster process of cancer cell killing. 
Shorter radiation treatment can have an im-
pact on complications time duration (reduced 
chances of normal tissue exposure) in com-
parison with other isotopes [16]. 90% of thera-
peutic dose is being deposit in 33 days in more 
homogeneous way with less total radiation to 
the patients. Moreover, relatively high energy 
level (29 KeV) provides 30% of greater pen-
etration of prostate tumor, if compared with 
palladium-103. It is also very important for 
patients, that short half- life of Cs-131 (only 7-9 
days) causes shorter restrictions of radiation 
exposure for dormitories and environment 
[16, 17]. The comparison of physical charac-
teristics of all these most popular isotopes has 
been made in Table 3. Tables 4 and 5 presents 
detailed decay data of I-125 and Pd-103. 
Despite biological models and better knowl-
edge of radiosensitivity of tumors and normal 
tissue there are insuffcient data to defi nitely 
decide which isotope is more effective in 
Fig. 1. Permanent implant used in brachytherapy
Fig. 2. Examples of I-125 implants used in brachytherapy
4.5 mm
3.0 mm
4.5 mm
0.5 mm
titanium
0.5 mm
titanium
Model 6702
Model 6711
I-125 absorbed 
on ion exchange 
resin
I-125 absorbed 
on silver rod
0.8 mm
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Pd-103 Decay 
Days Comment % Pd-103 Remaining
0 Implant Day 100
2  92.5
4  85.5
6  79
8  73
10  67
12  62
14  57
16  52
17 1st Half Life 50
18  48
20  44.5
22  41
24  38
26  35
28  32
30  29.5
32  27
34 2nd Half Life 25
36  23
38  21
40  19.5
42  18
44  16.6
46  15.2
48  14
50  13
51 3rd Half Life 12.5
54  11
57  9.7
60  8.6
64  7.3
68 4th Half Life 6.25
75  4.7
85 5th Half Life 3.125
90  2.5
102 6th Half Life 1.5625
112.5  1
prostate cancer treatment. There is no clear 
agreement beetwen the scientists about alfa/
beta value which is usefull in calculating 
biological dose. Prospective clinical studies 
comparing HDR and LDR monotherapy are 
ongoing but most of authors esthabilished 
alfa/beta ratio as 1,5. According to this value 
for acute effects we can calculate that HDR 
brachytherapy is much more effective for low-
er alfa/beta values. For the higher one seed’s 
therapy seems to be a better choice for pa-
tients (higher biological dose applyed). Apart 
from that, the biologic effectiveness of the 
radiation treatment strongly depends on dose 
rate and the radiosensitivity of the tissue. It 
is well-known fact that higher dose rate apply 
I-125 Decay 
Days Comment % I-125 Remaining
0 Implant Day 100
7  92.2
14  85.1
21  78.5
28  72.4
35  66.7
42  61.6
49  56.8
56  52.4
60 1st Half Life 50
63  48.3 
70  44.5 
77  41.1 
84  37.9
91 34.9 
98  32.2
112  27.5 
120 2nd Half Life 25
150  17.8 
180 3rd Half Life 12.5 
198  10
240 4th Half Life 6.25 
300 5th Half Life 3.125 
360 6th Half Life 1.5625 
396  1.0 
Table 4. I-125 Decay Table Table 5. Pd-103 Decay Table
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equally great damage to both healthy and ma-
lignant cells of a organism. According to this 
signifi cant information, the knowledge about 
dose rate impact on biologic cell cycle, infl u-
ences the physicians to select the modalities 
of treatment (HDR or LDR) as well as the sort 
of radioactive sources [13]. 
The comparison of temporary and 
permanent implants
Two brachytherapy treatment modalities (LDR 
and HDR) can be only compared in monothera-
py in patients with low staged tumors. In most 
cases LDR-BT is administrated as a single 
treatment in early detected prostate cancer. 
High-dose-rate (HDR-BT) brachytherapy is 
usually applied along with external beam ir-
radiation to patients with prostate tumors non 
qualifi ed by strict stage terms. HDR-BT is rela-
tively new as a monotherapy and at the moment 
there is limited data about the results and the 
complication rates in this indication [18,19]. In 
some publications HDR as radiation modality 
has ability to deposit higher dose to the tumor 
and lower dose to organs at risk [18]. It produc-
es more inhomogeneous dose distribution in 
the target (higher V150 and V200 parameters) 
but due to fl exibility of planning, inhomogene-
ity can be used to keep the dose of organs at 
risk low while increase the dose on the periph-
ery of the gland. Because of impossibility to 
remove or adjust permanent seeds, there is no 
way to compensate isodose by computer plan-
ning system after implantation. Moreover, it is 
advisable to use high-dose rate brachytherapy 
in prostate cancer, suspected of extracapsular 
spread, in order to achieve better coverage of 
this area, if compared with gland only targeted 
seeds therapy, because seed migration can be 
signifi cant problem in this case. Apart from the 
dosimetry the larger dose per fraction seems 
to respond better in local control of prostate 
cancer treatment. According to radiobiologi-
cal considerations, the use of HDR-BT in these 
kind of tumors is far more practical [18]. Af-
ter temporary HDR-BT there is no restrictions 
about patients radioactivity and possibility 
of seeds migration through the bloodstream 
outside the gland. Oedema’s therapeutic dose 
coverage trouble does not exist in temporary 
implantation procedure because of real time 
planning and short treatment time.
There are also some positive aspects about 
using LDR-BT in radiation oncology. Patients 
with cancers at early stage are able to attend 
one day procedure in surgery with all cost 
profi ts according to this fact. In United States 
single LDR-BT costs much less than EBRT 
along with HDR-BT. The comparison of time 
duration in these two modality treatments 
is another serious plus point of using seeds 
therapy (one day versus 4–5 weeks). This 
technique has yet another strong argument – 
many cancer centers has a lot of experience 
in performing permanent implants, usually 
about 5 years longer than modern HDR pros-
tate brachytherapy. Wide availability of this 
treatment and its frequent performing, give 
rise to increased number of publishing data 
with generally good results in treatment of 
organ confi ned prostate cancer [19]. Seeds 
implants therapy, performed by experienced 
brachytherapist, gives almost the same qual-
ity of glands dose coverage as the temporary 
implants technique. Summarized comparison 
of both brachytherapy techniques was pre-
sented at ASTRO Meeting in Phoenix, 1998 
(Table 6). 
Implantation technique
Preoperative workup before low-dose-rate 
seeds insertion includes mechanical bowel 
preparation, prophylactic intravenous anti-
biotics, continued per os for several days af-
terwards. Before the procedure patients with 
history of deep vein thrombosis is being given 
heparin subcutaneously to prevent any com-
plications in connection with these blood con-
dition. Because of signifi cant risk of perineal 
haemorrhage, the rest of the procedure can-
didates are to stop receiving anticoagulants, 
including aspirin, nonsteroidal anti-infl amma-
tory drugs or warfarin [20]. In the operating 
room, a patient is placed under general or spi-
nal anesthesia in dorsal lithotomy position. Af-
ter cathetherization of contrast (Renografi n) 
or air fi lled gel that are usually used to visual-
ize the urethra and to differentiate the bladder 
from the prostate. It is also important to ex-
clude scrotum and testis from radiation fi eld 
by fi xing them with tape or towel clips. First 
step of the procedure is the necessity of deter-
mining the shape and size of the gland before 
needles insertion by initial trans-rectal ultra-
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sound examination (TRUS). It can be done a 
few weeks before seeds insertion (preimplant 
treatment planning) or can be performed on 
the day of the procedure (intraoperative treat-
ment planning). A biplanar probe at 5, 6, or 
7.5 MHz of frequency, gather ultrasound vi-
sualization of prostate localization at 0,5 cm 
intervals, compared with the one after needles 
insertion. Treatment plan prepared should 
contain several informations such as a needle 
location, number and strength of seeds and 
shape and volume of the target. To achieve ex-
act dose inside the prostate there is necessity 
to use nomograms (inadequate amount activi-
ty per volume) combined with real-time TRUS 
and treatment planning system. 
Transrectal ultrasound equipment is com-
bined with special template used for seeds 
implantation and by guiding creates stepping 
unit. Before proper procedure it is important 
to measure the distance from bladder base to 
template. Only then, two stabilising needles 
are being inserted through the template just 
posterior to the urethra on either side of the 
midline [21]. Because of movement of the 
prostate, during the procedure a pre-plan is 
created in order to minimize the risk of po-
sitioning errors. The loading pattern indicate 
co-ordinates in the computer planning system 
in connection with the templates stepping unit 
[21]. That gives the physicians exact points 
to insert each needle and number of seeds. 
When the pre-plan is done 20 cm long 18 gauge 
needles are inserted and after consulting two 
plans (before and after insertion) radioac-
tive seeds are placed into the prostate gland 
through Mick applicator (loose seeds tech-
nique). The schema of patients positioning and 
implantation technique is presented in Figure 
3. (Figure 3) Withdrawing each needle should 
be done very carefully to avoid source migra-
tion inside the gland. Once the procedure has 
The following table was compiled by the HDR Prostate Working Group and presented to radiation oncologists at the American Society of 
Therapeutic Radiology and Oncology (ASTRO) meeting in Phoenix, October 1998.
  High Dose Rate  Permanent Seed
 Conformal treatment ++++ ++++
 Target accuracy ++++ ++++
 Ability to treat extracapsular extension  ++++ +
 Ability to treat seminal vesicles  ++++ ++
 Ease of control of radiation  ++++ ++
 Lack of cold/hot spots  ++++ ++
 Control of critical organ dose  ++++ ++
 Modify dose distribution ++++ +
Need for external beam  yes/sometimes  no/sometimes
 Monotherapy  + +++
 Experience of physician  crucial crucial
 Pre-planning dosimetry  not needed extensive (TRUS)
 Post-implant dosimetry  not needed extensive (CT)
 Stages treated  all, T1–T3  T1–T2
 Gland volume>60 cc at time of implant  less diffi culty more diffi culty
 Pubic arch interference at time of implant  less of a problem can’t be done
 Prior TURP  less of a problem can’t always be done
 Final dose verifi cation  pre-treatment  post-treatment
 Symptom duration  weeks  months
Implant cost  higher  lower
Table 6. Comparison of high-dose-rate temporary implants and permanent seed implants
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been completed, the position of implants must 
be observed under fl uoroscopy and ultra-
sonography. Usually there is no possibility of 
removing seeds after insertion and if a “cold 
spots” are observed, a few extra seeds can be 
added to cover them. Performing a fi nal CT 
scan of the prostate and postimplant dosime-
try ends up the whole procedure of LDR seeds 
implantation in prostate cancer treatment. 
The patient leaves the theatre cathetherized 
and after removing it, can be discharged 
home the next day [20]. Schematic positioning 
of implants is presented in Figure 4 a and 4 b, 
radiogram with visible implants – in Figure 5. 
There is another advanced technique of seeds 
implantation worth od mentioning. In stranded 
seeds technique the point is to implant radio-
active sources embedded in a polymer strand 
of glycolide, lactide and polydioxanone spaced 
from 5 mm to over 50 mm apart and placed in 
18-gauge needle. The main advantages of this 
technique using is signifi cant improvement 
in D90 parameter without increase of toxic-
ity rate and less number of seeds migration 
incidences [22].
Dosimetry
Apart from dosimetric planning of the implant 
before or during seed insertion, American 
Brachytherapy Society (ABS) recommends 
postimplant dosimetry in all patients for best 
optimal care [9]. According to availability, 
cost and exact way to visualize a prostate with 
implanted seeds, CT-based dosimetry is in the 
world-wide use nowadays. CT scanning has to 
be determined by each center at a consistent 
postoperative intervals to check the evalu-
Fig. 3. Setting the needles using permanent implant 
technique
Fig. 4 a i b. Schematic images of implants and circumja-
cent Organs at Risk (OAR) – Bladder, Urethra, Rectum
blaader
Blaader
a
b
radioactive 
seed
tumour
prostate
Prostate 
Containine
Urethra
Rectum
Fig. 5. X-ray image of implanted I-125 implants [20]
ation of implanted seeds position and this 
intervals should be reported [20]. On every 
digital examination physicians with physicist 
should obtain isodoses overlapping the gland 
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at 50%, 80%, 90%, 100%, 150%, and 200% of 
the prescribed dose and compared with dose-
volume-histograms (DVH) on previous CT 
scans. Nevertheless, ABS recommends for all 
centers to perform DVH and report the D90 
value (dose received by 90% of the target vol-
ume) and the V 100 (volume received 100% 
of the prescribed dose) [9]. To prevent any 
serious complication of organs at risk (OAR) 
the rectal and the urethral doses should be 
reported and correlated with patient ailments 
during the interview. In addition to the treat-
ment, post implant radiographs can be per-
formed to verify the seeds location and their 
number. The dose is usually prescribed at the 
periphery of the target volume and for J-125, 
Pd-103 – it equals to 145, 125 Gy, respectively. 
The prescribed dose in the centre of radiated 
volume should not be higher than 150%, what 
can be achieve by decreasing the number of 
seeds from potential “hot-spots” [21]. Oedema 
of the gland after implantation procedure is 
the last point worth of mention in this para-
graph. Higher volume of prostate causes 
worse value of therapeutic dose cover. Using 
treatment margin value (TM) in treatment 
planning should help to cover exact volume of 
the gland. Anyway, role of treatment margin 
around the prostate is to cure possible micro-
scopic disease spread outside the capsule. TM 
in most cases should equal not less than 3-5 
mm and in many publications [23]. Example 
of treatment plan is presented in Figure 6.
Selected outcomes presentation
Several authors publishing their data in 
medical periodicals generally confi rmed 
good results in prostate cancer treatment by 
LDR-BT alone. Implantation of low-dose-rate 
seeds in most cases is used as a single mo-
dality treatment with or without concurrent 
androgen deprivation. The main reason of 
problems in comparison between published 
series are: selection criteria, nonuniformity 
of end points, different follow-up times and 
hormonal therapy used by medical centers 
worldwide. Publication data with longer 
follow-up are known as the most authorita-
tive results (about 5 years). Authors from 
Memorial Sloan-Kettering Cancer Center 
reported the 5-year tumor control and toxic-
ity outcomes for patients with localized pros-
Fig. 6. Image assisted treatment planning in prostate 
cancer. Transverse ultrasound image showing the PTV, 
Urethra and Rectum delineated and the dose distribution 
in a LDR Iodine permanent implant. Isodose levels are 
given for the prescribed dose of 140 Gy as well as for 250 
Gy and 110 Gy. [20]
250Gy
140Gy
110Gy
rectum
urethra
PTV
tate treated with I-125 permanent implanta-
tion [32]. The amount of 2693 patients with 
prostate cancer were treated between Janu-
ary 1998 and June 2002 with LDR-BT alone 
by using real-time intraoperative treatment 
planning system. The 5-year PSA relapse-
free survival rates for low and intermediate 
risk patients – according to the ASTRO defi -
nition – were 96% and 89%, respectively. The 
authors stated that D90 was correlated to 8 
year PSA relapse free survival (PRFS). On 
multivariate analysis in patients with post-
implant dosimetry D90 was a signifi cant pre-
dictor for PRFS. There is an agreement that 
parmeter D90 needs to be reported in seed 
publication. Acute urinary symptoms had 
38% of patients, but within a median time of 6 
months, 63% of them have been relieved from 
these symptoms. The late rectal toxicity was 
noticed at 1%, late rectal bleeding (Grade 2) 
at 7%. Apart from good biochemical control 
outcomes this publication demonstrated that 
real-time planning methods can consistently 
and reliably deliver the intended dose distri-
bution to achieve an optimal therapeutic ratio 
between the target and normal tissue [32].
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Five European countries (France, Finland, 
Italy, Spain and the UK) have gathered their 
data in interstitial LDR treatment of prostate 
cancer as a monotherapy and published it in 
July 2006. Between May 1998 and August 
2003, the number of 1050 patients with loca-
lised disease in stage T1-T2 were treated by 
brachytherapy [33]. They were divided into 
three main risk groups (ASTRO defi nition) 
with percent disposition of 63.6%, 28.3%, 6.3% 
respectively. Unfortunately from whole num-
ber of patients only 364 of them were evalu-
able by the Kaplan-Meier method for deter-
mining freedom from biochemical failure in 
36 months time. The biochemical progression-
free rate at 3 years for each: low, intermedi-
ate and high risk groups, was noticed at 93%, 
88%, 80% respectively. Although in this pub-
lication authors reports preliminary data, the 
outcomes of LDR monotherapy were gathered 
from different medical centers and after sta-
tistic evaluation, confi rmed good results de-
pending on stratifi cation into risk groups [33]. 
Merrick et al. from April 1995 to October 2002 
Author Number 
of patients
Risk group Treatment 
schedules(monotherapy)
Follow-up Results
Guedea F 
[33]  
364 I, II, III LDR BT 
(results of 4 centres)
36 months BC
93.0% I
88.0% II
80.0 III
Bladou F 
[36]  
260 I, II, III LDR BT (I–125) 29.5 months DFS
93.8% (all groups)
97.7% (I).  
Radge H 
[37]  
619 I, III LDR BT I–125 (I)             
Pd–103 (III)
13 years  DFS
76% I
80% III
Sharkey J 
[38]  
166 I LDR BT Pd–103 + HT 5 years FFPF
86%
Merrick GS 
[39]  
32 I, II, III LDR BT 26.4 months BC
100% 
Kollmeier MA 
[40]  
243 I, II, III LDR BT 
(I–125, Pd–103) + HT
8 years FFPF 
88.0% I
81.0% II
65.0% III
Prada PJ 
[41]  
275 I, II, III LDR BT 
(I–125, Pd–103)    
5 years 96% OS
97% DFS
99% BC
Merrick GS 
[42]  
119 I, II, III LDR BT 7 years BC
93.1% I
100.0% II
95.2% III
Stock RG 
[43]  
79 I, II LDR BT 
(I–125, Pd–103)     
24 months FFPF
76%
BC – biochemical control rate, DFS – progression–free survival rate, OS – overall survival, FFPF – freedom from PSA failure rate 
Risk groups:
I   (TNM cT1–cT2a, Gl < 6, PSA < 10 ng/ml)
II  (TNM cT2a–cT2c, Gl 7, PSA 10–20 ng/ml)
III (TNM > cT3, Gl 8–10, PSA > 20 ng/ml)
LDR BT – low–dose–rate brachytherapy
HT – androgen deprivation therapy
Table 7. Treatment results of LDR-BT monotherapy published by different authors 
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gathered data about outcomes (biochemical 
progression-free survival-BPFS) in hormone-
naive men aged <54 years who underwent 
brachytherapy with or without external beam 
radiation therapy [34]. The patients (n=108) 
without hormonal treatment were treated 
with low dose rate interstitial brachytherapy 
for clinical stage T1C-T2C N0M0. The mean 
observation time was 5,3 years for all patients. 
No patient had a seminal vesical biopsy or 
pathological lymph node staging. BPFS was 
defi ned by a prostate-specifi c antygen (PSA) 
lavel of less or equal 0,4 ng/ml after the na-
dir. Patients were assigned to risk groups ac-
cording to Memorial Sloan-Kettering Cancer 
Center criteria. Several clinical, treatment 
and dosimetric parameters were analysed for 
their effect on BPFS. After observation time, 
authors observed that for the entire group the 
actuarial 8-year biochemical progression-free 
survival rate was 96%, for the low-risk was 
96% for the low-risk group, 100% for the in-
termediate-risk, 75% for the high-risk group. 
For patients without any biochemical relapse 
(biochemically desease-free), the median 
PSA lavel was 0,05 ng/ml. In a multivariate 
analysis, only pretreatment PSA level pre-
dicted biochemical control, while dosimetry 
variables after treatment were almost statis-
tically signifi cant. It is important to take into 
consideration the fact of observing exellent re-
sults with brachytherapy in patients with low 
and intermediate risk disease and signifi cant 
worse in higher risk group. Apart from that 
hormone-naive patients aged less or equal 54 
years have a high probability of good 8-year 
BPFS after permanent interstitial brachyther-
apy with or without EBRT [34].
Schiffl er Cancer Center in West Virginia 
published an article about outcomes in pros-
tate cancer treatment at hormone-naive pa-
tients with high-risk disease after permanent 
prostate brachytherapy [35]. Sixty-six men 
underwent LDR-BT with the use of either Pd-
103 or I-125 from April 1995 to October 1999. 
Brachytherapy boost was preceded by supple-
mental external-beam radiation therapy in 
most of them (98,5%) without additional an-
drogen therapy. After different follow-up time 
(ranged 19.8 - 79.7 months), authors established 
the 5-year actuarial biochemical disease-free 
survival rate as 79.9% (defi ned by ASTRO con-
sensus defi nition). Moreover, Merrick with his 
coworkers found out that preimplantation level 
of PSA was the only treatment parameter that 
predicted biochemical failure. These results 
proved that more or less hormone-naive pa-
tients with high-risk disease have a high rate 
of 5-year biochemical disease-free survival 
after combined radiation therapy alone [35]. 
Tables 7 and 8 show selected results about 
permanent brachytherapy and external beam 
radiation therapy in several publications. 
Complications
Rapid development of new computer plan-
ning systems and the use of modern technol-
ogy  are very helpful to upgrade the quality of 
treatment.However, it is not possible to avoid 
certain complications after implantation pro-
cedure. In the fi rst 24 hours after therapy it 
is frequent to observe haematuria. Urinary 
symptoms are the most common side effects 
of the LDR brachytherapy. Symptoms such 
as a dysuria, frequency or urgency urinating 
and especially an inability to empty the blad-
der completely, may occurs and last in various 
cases even up to several weeks. These irrita-
tive acute symptoms can be relieved by alfa 
blockers, anti-spasmodic or infl ammatory 
drugs and eliminated in some patients over 
time. If the bladder cannot be emptied for lon-
ger period of time, temporary self-catheter-
ization may be helpful to insure proper drain-
age. Nevertheless, 34-45% of patients notice 
urinary symptoms from 0,5-1 year after seeds 
implantation [20]. 
Transurethral resection of the prostate 
(TURP) followed by LDR-BT may increase 
the risk of urinary incontinence in such pa-
tients. The incidence rate of incontinence is 
10-35% in the fi rst few months, with few pa-
tients having any leakage in 1 year [20]. In the 
other publication authors reported develop-
ment of the symptoms risk less than 10% [11]. 
Determining of volume mass of the gland by 
ultrasound visualization before the procedure 
can minimize the risk of this symptoms after-
wards. Urethral stricture occurs in 3-6% of 
patients and may require urethral dilatation.
Rectal complications are reported in more 
or less 30% of patients include painful bowel 
movements, urge and diarrhea. In the fi rst 
year these symptoms become less severe and 
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after that time only 2% of cases have it per-
sistent [20]. Rectal bleeding can be observed 
at 1- 20% of patients depending on published 
data. Prostatorectal fi stulas occur in 0,5-1% 
of all patients in published series [20,21,25]. 
In addition, ulcerations on the anterior rectal 
wall overlying the prostate after LDR-BT pro-
cedure can be associated with increased rate 
of fi stula formation [24]. As a biopsy fi ndings, 
1% of patients can developed proctitis which 
was observed by Blasko et al. after I-125 seeds 
implantation [8].
In 33% of patients, LDR brachytherapy can 
cause complications in sexual functions and 
activity with concurrent decrease of semen 
volume. In several reports the problem of im-
potence is not signifi cant in comparison with 
sexual disorders after radical prostatectomy 
[26]. Generally 2,5-20% of patients can suffer 
from this kind of problem but they can  usu-
ally be helped with Viagra and other drugs or 
devices. Moreover, Wallner et al. after three 
years of observation noticed that potency can 
be maintained in 81% of men [27]. Kaye et al 
reported degree of potency decrease one year 
after procedure in 75% of patients [28]. Sex-
ual disfunctions after radical prostatectomy 
and this rather permanent condition is a well 
known complication.
Several publications in the medical lit-
erature treats about seeds migration in few 
months after implantation procedure [29,30]. 
Stone and al. examined 238 patients that un-
derwent implantation with either I-125 or Pd-
103 and applied a routine chest x-ray every 4 
months after procedure. For total of 21,654 
Table 8. Results of treatment combination (EBRT plus LDR-BT) published by different authors
Author Number 
of patients
Risk group Treatment 
schedules(monotherapy)
Follow-up Results
Wallner K 
[44]     
112 (risk group I) I, II, III EBRT (44 Gy) + Pd 103 (90 Gy) v 
EBRT (20 Gy) + Pd-103 (115 Gy)
3 years 84% DFS
94% DFS
Sylvester JE 
[45] 
223 I, II, III EBRT (45 Gy) + I-125, Pd-103 15 years  BFFS
88% (I)
80% (II)
53% (III)
Sherertz T 
[46]      
156 II, III EBRT (44 Gy) + Pd 103 (90 Gy) v 
EBRT (20 Gy) + Pd-103 (115 Gy)
3 years overall 
DFS
86%  
 Stock RG 
[47]      
43 III HT + EBRT + Pd-103 4 years FFPF 
74%
Orio P 
[48]      
179 II, III EBRT + Pd-103 3 years overall 
DFS
79%  
Peschel RE 
[49]      
68 I, II, III EBRT (45 Gy) + I 125 (110 Gy) v 
EBRT (45 Gy) + Pd-103 (98 Gy)
5 years 72% DFS
74% DFS       
Merrick GS 
[50]       
668 I, II, III HT + EBRT + Pd-103, I-125 8 years DFS
98.2% (I)
98.4% (II)
88.2% (III)
FFPF – freedom from PSA failure rate, DFS – progression–free survival rate, FFPF – freedom from PSA failure rate, BFFS – biochemical 
failure survival rate
Risk groups:
I   (TNM cT1– cT2a, Gl < 6, PSA < 10 ng/ml)
II  (TNM cT2a–cT2c, Gl 7, PSA 10–20 ng/ml)
III (TNM > cT3, Gl 8–10, PSA > 20 ng/ml)
EBRT – external beam radiation therapy
HT – androgen deprivation therapy
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implanted seeds only 10 (0.005%) were found 
in the lungs of 4 patients who also underwent 
embolus disease [29]. Although, the frequency 
of this complication event is rather rare, phy-
sicians should always consider the possibility 
of postimplant seeds migration in the whole 
body. Selected complication data published by 
several authors have been gathered in table 9. 
Patient’s care and follow up
The Foley catheter can be removed approxi-
mately in the next day after procedure, when 
urine ability of patient is good enough and 
there is no signs of active haemorrage. It is 
recommended for a patient to drink plenty of 
fl uids for the fi rst two days after treatment to 
prevent serious infections of urine pass. To re-
duce the swelling of perineum caused by the 
needles, applying of a ice pack seem to be a 
good idea. Because of the risk of seeds lose 
during urination or sexual act, patients should 
be receiving a special packet home to protect 
other people from LDR radiation. During 
sexual intercourses, patients must remember 
about the need of using condoms within two 
months. The necessity of keeping away chil-
dren or pregnant women for two months after 
procedure is a basic point in environment ra-
diation safety. I-125 emits very low-dose-rate 
energy radiation and it is stopped inside the 
target in most cases [31]. In addition, pro-
longed close contact with young children and 
Author Treatment 
schedules
Rectal 
dysfunction
Urinal 
dysfunction
Sexual 
dysfunction
Median 
follow-up
Shah MD
[51]
LDR (I-125 145 Gy 
or Pd-103 120 
Gy)+/- HT
Acute toxicity: 
Proctitis grade I 5.3%
Incontinence grade I 5.3%
Haemorrhage grade I 8.3%
Diarrhoea 16.7%
ND ND 41 months
Merrick GS 
[52]
LDR (I-125 145 Gy 
or Pd-103 120 Gy)
ND ND Potency 
preservation 
rate 50.5%
36 months
McElveen
[53]
LDR I-125 145 Gy ND Incontinence 
Grade 1 26% 
Grade 2  5%
ND 47 months
Bettermann J.J.
[54]
LDR I-125 145 Gy Intestinal problems 1.6%
Rectal ulcer 0.4 %
Urinary complications 
7.23% 
(including acute retention 
1.6%, 
urethral strictures 1.2 %)
ND 29.2 
months
Blank L
[55]
LDR I-125 160 Gy +- 
EBRT 40 Gy
Proctitis, bleeding 3.92%
Nausea, vomiting 5.88%
Urinary 
incontinence  0.98%
Stricture 1.96% 
Acute retention  4.9%
48%  Potency 
preservation 
rate
102 months
Blasko JC
[56]
LDR (I-125 145 Gy 
or Pd-103 115 Gy)  
+ EBRT 45 Gy
Grade 2 6%
Grade 3 2%
Recto-urethral fi stulas  0.5%
ND ND 58 months
Salem N
[57]
LDR I-125 144 Gy ND Grade 1 34%
Grade 2 10%
Grade 3 16.7%
ND 14 months
Keyes MD
[58]
LDR (I-125 144 Gy 
+/- HT +- TURP.
ND acute urinary retention 
12.7% prolonged 
urinary obstruction 5%
ND 39.1 
months
ND - no data in publication, TURP - transurethral prostate resection.
Table 9. Complications of prostate cancer LDR treatment in different publications
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pregnant women is not eliminating any poten-
tial radiation risk for them. Patient should be 
discharged home with fi ve days continuation 
of antibiotics or analgesics. To prevent any 
urinary troubles according to glands postpro-
cedure oedema, corticosteroids and/or non-
corticosteroids antiinfl ammatory drugs can 
be used for several days. 
Blood test (PSA) is performed once in each 
month after LDR brachytherapy for a patient 
follow up. The CT Scan is used to control seeds 
positions inside the prostate and to visualize 
isodoses that encompasses it. Postimplant 
planning and dosimetry based on CT made 
after 4-6 weeks after the procedure is of im-
portance with regard to the quality of the im-
plant. The chest X-Ray is a digital examina-
tion to check if any seeds have escaped from 
the target to lungs via bloodstream. A physical 
examination and a blood test are repeated by 
urologist and radiation oncologist once every 
three months. It is also possible to check can-
cer regression by transrectal biopsy, two years 
after the implantation [59].
CONCLUSIONS
Application of low-dose-rate permanent im-
plants in localized prostate cancer has estab-
lished its importance worldwide. LDR-BT is 
a major competition nowadays with radical 
prostatectomy in early detected tumors, es-
pecially in older men. As a single modality 
treatment procedure has been applied in pa-
tients from low risk group without any risk 
of extracapsular extension. Combination of 
brachytherapy with external beam radiation 
therapy can be useful in higher risk groups 
with addition of androgen ablation therapy. In 
most cases brachytherapists use two kinds of 
encapsulated isotopes in prostate cancer ther-
apy: Iodine-125 and Palladium-103. However, 
good results and more convenient therapy for 
the patients, this method is still an exclusive 
modality treatment, because of its high cost of 
single procedure. Anyway similar cost-effec-
tivness fact of external beam radiation, radi-
cal prostatectomy and seeds therapy should be 
highlight here [60]. We think that for patients, 
it is much more desirable to spend only three 
hours in an outpatient surgical clinic for a seed 
implantation than to undergo major abdomi-
nal or perineal surgery, that requires weeks 
of recovery, or in other case – to submit a pa-
tient for protracted daily radiation treatments 
which last for several weeks. Favorable toxic-
ity profi le of permanent implants brachyther-
apy in comparison with all estabilished cura-
tive modalities particularly to sexual function 
makes it an effective weapon of prostate can-
cer treatment.
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